New Immunotherapy Findings from
Our news journalists obtained a quote from the research, "Here, I suggest that the lack of anticipated responses could be because cancer cells continuously mutate, whereas the population of tumor antigens from the excised tumor is genetically static, and because there is an absence of biologic mechanisms to facilitate intratumoral DC retention, which is needed for DC pulsing. I hypothesize that stable tumor transfection with fetal liver tyrosine kinase 3 ligand (Flt3-L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) DNAs will induce homing, propagation and maturation of intratumoral DC. This must be followed by drug-induced apoptosis of tumor cells, to ensure the release of tumor antigens for DC pulsing."
According to the news editors, the research concluded: "Then, regardless of any mutation of tumor cells, they would always incite DC propagation and maturation, pulsing and antitumor immunity."
For more information on this research see: Dendritic cell-based cancer immunotherapy: the stagnant approach and a theoretical solution. Drug Discovery Today, 2014;19(7):834-837. Drug Discovery Today can be contacted at:
The news correspondents report that additional information may be obtained from
Keywords for this news article include: Antigen-Presenting Cells, Biotechnology, Cancer,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- PBS Series Examines America's Demographic Shift
- Tim Cook Has Proved That Apple is His Baby
- Why the Bond Market Isn't as Safe as You Think
- Lexus Luxury Compact Sedan Wins Buyers
- Royals Beat A's in 12-inning Wild Card Thriller
- What to Look for in Mich. Jobs Market
- Construction Spending Down Again for August
- Review: Pay by Phone or Just Keep Using Plastic?
- Obama Seeks Traction From Economic Recovery
- Dallas Parents Fear Students Exposed to Ebola